PPMD and the Muscular Dystrophy Association recently provided insights into the current status of the Duchenne nomination to the federal Recommended Uniform Screening Panel (RUSP) for newborn screening following the dissolution of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC). This briefing provides a timely overview of where the nomination stands, what this change means, and what potential next steps may look like. The discussion includes strategic options and key partnerships necessary to continue advancing nationwide newborn screening for Duchenne.